ABC评分在ENGAGE AF-TIMI 48房颤患者中评估卒中/系统性栓塞与出血风险的表现
本研究在ENGAGE AF-TIMI 48试验的8705例房颤患者中前瞻性验证ABC-stroke和ABC-bleeding评分。结果显示两评分校准良好,对卒中/系统性栓塞的c指数为0.67(95%CI 0.65-0.70),优于CHA2DS2-VASc的0.59(P<0.001);对 major bleeding的c指数为0.69(95%CI 0.66-0.71),优于HAS-BLED的0.62(P<0.001)。ABC-bleeding预测1年出血风险>2%的患者从依度沙班治疗中获益更大。
要点
- ABC-stroke和ABC-bleeding评分在抗凝房颤队列中校准良好且区分度优于传统评分。
- ABC-bleeding预测1年出血风险>2%者接受依度沙班较华法林获益更大。
- 两评分可在CHA2DS2-VASc和HAS-BLED风险分层内进一步区分患者。
核心结论
- ABC-stroke和ABC-bleeding评分在ENGAGE AF-TIMI 48抗凝队列中校准良好,区分度分别优于CHA2DS2-VASc和HAS-BLED评分。
- ABC-bleeding评分预测1年出血风险>2%的患者从依度沙班治疗中获益更大。
研究设计与样本
- ENGAGE AF-TIMI 48为多国随机试验,比较口服Xa因子抑制剂依度沙班与华法林在房颤且CHADS2≥2患者中的疗效。
- 嵌套前瞻性生物标志物研究纳入8705例患者,检测基线及12个月时hsTnT、NT-proBNP和GDF-15。
- 验证ABC-stroke(年龄、既往卒中/TIA、hsTnT、NT-proBNP)和ABC-bleeding(年龄、既往出血、血红蛋白、hsTnT、GDF-15)评分。
主要发现
- 基线hsTnT中位数13.7 ng/L(IQR 9.6-20.4),NT-proBNP 811 pg/mL(IQR 386-1436),GDF-15 1661 pg/mL(IQR 1179-2427)。
- hsTnT、NT-proBNP和GDF-15升高均独立与卒中/系统性栓塞风险增高相关(P<0.001)。
- hsTnT和GDF-15升高独立与major bleeding风险增高相关(P<0.001)。
- ABC-stroke对卒中/系统性栓塞的c指数0.67(95%CI 0.65-0.70),高于CHA2DS2-VASc的0.59(95%CI 0.57-0.62),P<0.001。
- ABC-bleeding对major bleeding的c指数0.69(95%CI 0.66-0.71),高于HAS-BLED的0.62(95%CI 0.60-0.64),P<0.001。
关键数值与推荐
- ABC-stroke评分组成:年龄、既往卒中/TIA、hsTnT、NT-proBNP。
- ABC-bleeding评分组成:年龄、既往出血、血红蛋白、hsTnT、GDF-15。
- ABC-stroke和ABC-bleeding评分可在CHA2DS2-VASc和HAS-BLED风险类别内进一步分层(P<0.001)。
- ABC-bleeding评分预测1年出血风险>2%的患者接受依度沙班较华法林获益更大。
临床怎么用
- 在房颤抗凝患者中可考虑使用ABC-stroke和ABC-bleeding评分辅助评估卒中与出血风险。
- ABC-bleeding评分高(1年出血风险>2%)者可能从非维生素K拮抗剂口服抗凝药(如依度沙班)中获益更多。
局限性
- ABC评分在ENGAGE AF-TIMI 48试验队列中验证,外部适用性仍需进一步研究。
- 原文未报告ABC评分相较于传统评分的净重分类改善等量化指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ABC (age, biomarker, clinical history)-stroke and ABC-bleeding risk scores incorporate clinical variables and cardiovascular biomarkers to estimate risk of stroke or systemic embolic events and bleeding, respectively, in patients with atrial fibrillation. These scores have been proposed for routine clinical use, but their performance in external cohorts remains uncertain. METHODS: ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) was a multinational randomized trial of the oral factor Xa inhibitor edoxaban in patients with atrial fibrillation and a CHADS2 score ≥2. We performed a nested prospective biomarker study in 8705 patients, analyzing baseline high-sensitivity troponin T (hsTnT), NT-proBNP (N-terminal B-type natriuretic peptide), and growth differentiation factor-15 (GDF-15), as well as in serial samples after 12 months. The ABC-stroke (age, prior stroke/transient ischemic attack, hsTnT, NT-proBNP) and ABC-bleeding (age, prior bleeding, hemoglobin, hsTnT, and GDF-15) scores were tested. Hazard ratios were adjusted for estimated glomerular filtration rate and the components of the CHA2DS2-VASc and HAS-BLED scores, respectively. Discrimination and reclassification were compared with these established scores. RESULTS: Median baseline hsTnT, NT-proBNP, and GDF-15 levels were 13.7 ng/L (25th-75th percentiles, 9.6-20.4 ng/L), 811 pg/mL (386-1436 pg/mL), and 1661 pg/mL (1179-2427 pg/mL), respectively. Elevated hsTnT, NT-proBNP, and GDF-15 were independently associated with higher rates of stroke or systemic embolic events, and elevated hsTnT and GDF-15 were independently associated with higher rates of major bleeding ( P<0.001 for each). The ABC-stroke and ABC-bleeding scores were well calibrated and yielded higher c indexes than the CHA2DS2-VASc score for stroke or systemic embolic events (0.67 [95% CI, 0.65-0.70] versus 0.59 [95% CI, 0.57-0.62]; P<0.001) and HAS-BLED score for major bleeding (0.69 [95% CI, 0.66-0.71] versus 0.62 [95% CI, 0.60-0.64]; P<0.001), respectively. The ABC-stroke and ABC-bleeding scores stratified patients within CHA2DS2-VASc and HAS-BLED risk categories ( P<0.001 for both). Patients with ABC-bleeding scores predicting a high 1-year risk of bleeding (>2%) derived greater benefit from treatment with edoxaban compared with warfarin. CONCLUSIONS: The ABC-stroke and ABC-bleeding scores evaluated in this anticoagulated clinical trial cohort were well calibrated and outperformed the CHA2DS2-VASc and HAS-BLED scores, respectively. These scores may help identify patients most likely to derive a benefit from treatment with non-vitamin K antagonist oral anticoagulants. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00781391.
引用
- Berg DD, Ruff CT, Jarolim P, et al. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. Circulation. 2019. PMID: 30586727. doi:10.1161/CIRCULATIONAHA.118.038312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。